Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganwu
- Development stage
- Phase 4
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
**Ganwu** is an intranasal influenza vaccine approved in China, developed by Changchun BCHT Biotechnology Co. It provides moderate protection against laboratory-confirmed influenza, with an effectiveness of 15.2% (95% CI -2.3%-29.7%) against influenza-like illness (ILI) in children. The vaccine demonstrates a favorable safety profile with comparable incidence of solicited adverse events to controls.
- Brand names
- Ganwu
- Other names
- H1N1 live attenuated influenza vaccineH-1N1 live attenuated influenza vaccineH 1N1 live attenuated influenza vaccineSII H1N1 vaccinePandemic Influenza Vaccine (H1N1) (Live Attenuated, Nasal)
Beyond the preview
Go deeper on Ganwu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganwu.